Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 940-786-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 7 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 7 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Dose descriptor:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 9.6 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard for the eyes
Additional information - workers
For the human health endpoints, the most relevant/critical DNELs for Benzene, C15 -16 -alkyl derivs. are considered to be the DNELlong-term for worker dermal and inhalation exposures and for consumer oral, dermal and inhalation exposures. The worker dermal and inhalation DNELlong-term were calculated to be 9.6 mg/kg bw/day and 7.0 mg/m3, respectively. The consumer DNELlong-term for oral, dermal and inhalation exposures were calculated to be 0.5 mg/kg bw/day, 4.8 mg/kg bw/day and 1.8 mg/m3, respectively.
Discussion
Benzene, C15 -16 -alkyl derivs. is not considered to be hazardous to human health. Acute toxicity studies for read-across source substances via the oral and dermal exposure routes resulted in no mortality or other signs of toxicity at the limit doses. No significant effects were observed in acute skin and eye irritation studies, with only minimal effects observed at 100% dermal doses. In repeated dose studies the only effects were reduced body weight gain. Effects on survival and weight gain in the F1 and F2 generations in a reproductive toxicity study were observed at doses of 500 mg/kg bw/d and above. Effects in a developmental study were only observed at doses that were maternally toxic.
In addition, mutagenicity studies using both in vitro and in vivo methods demonstrate that the test substance was not mutagenic.
Because of the lack of significant toxicity observed in the suite of toxicity tests, the DNEL derivation was focused on the worst case situations, that is, long-term exposure to workers via both the oral and dermal routes. The NOAEL used to derive the DNELs was the lowest NOAEL from the reproductive toxicity chronic test with rats. The calculated DNELlong-term values for dermal and inhalation exposures were 9.6 mg/kg bw/day and 7.0 mg/m3, respectively. The calculated DNELlong-term values for consumer oral, dermal and inhalation exposures were 0.5 mg/kg bw/day, 4.8 mg/kg bw/day and 1.8 mg/m3, respectively
Benzene, C15 -16 -alkyl derivs. is not classified for any of the human health endpoints, nor is it classified as a PBT or vPvB. Benzene, C15 -16 -alkyl derivs. is classified for aspiration hazard due to its low viscosity and therefore exposure and risk characterizations have been completed.
DNEL long-term, workers, inhalation
For this DNEL, a similar procedure is applied as for the derivation of the dermal DNEL. However, since only oral long-term toxicity data are available, the oral NOAEL must first be converted to an inhalation value to use as the starting point. Using the formulae in Figure R.8-3 of Chapter R.8 (p.27) and the oral NOAEL of 50 mg/kg, the resulting inhalation NOAEC would be 88 mg/m3. Because this conversion includes interspecies exposure duration differences, no allometric scaling assessment factor is required . The remaining assessment factors are included as shown in the table below. The resulting DNELlong-term, workers, inhalation is equivalent to 7.0 mg/m3.
DNEL long-term, workers, dermal
For long-term, worker, dermal exposures, the DNEL is derived using the oral NOAEL as the starting point. This starting point oral NOAEL value must be corrected for route-to-route extrapolation. In accordance with REACH guidance document R.8, in the absence of data, no default factor (i.e. factor of 1) should be introduced for oral-to-dermal extrapolation, based on the assumption that dermal absorption will in general not be higher than oral absorption. However, for highly lipophilic substances (log Kow > 4), according to Section R.7.12.2.1 of REACH guidance document R7.C, a 10% default dermal absorption value is recommended for the purpose of risk assessment. Therefore a factor of 9.6 (ABSoral/ABSdermal = 96/10) can be used to correct the starting dose for absorption difference between routes. The next steps consist in applying assessment factors for interpecies difference, intraspecies variation, exposure duration, dose-response and quality of the database. The overall AF in this case again corresponds to 50 (see the table below). The resulting DNELlong-term, workers, dermal is equivalent to 9.6 mg /kg bw/day.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.8 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.8 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 25
- Dose descriptor:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 4.8 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Additional information - General Population
For the human health endpoints, the most relevant/critical DNELs for Benzene, C15 -16 -alkyl derivs. are considered to be the DNELlong-term for worker dermal and inhalation exposures and for consumer oral, dermal and inhalation exposures. The worker dermal and inhalation DNELlong-term were calculated to be 9.6 mg/kg bw/day and 7.0 mg/m3, respectively. The consumer DNELlong-term for oral, dermal and inhalation exposures were calculated to be 0.5 mg/kg bw/day, 4.8 mg/kg bw/day and 1.8 mg/m3, respectively.
Discussion
Benzene, C15 -16 -alkyl derivs. is not considered to be hazardous to human health. Acute toxicity studies via the oral and dermal exposure routes resulted in no mortality or other signs of toxicity at the limit doses. No significant effects were observed in acute skin and eye irritation studies, with only minimal effects observed at 100% dermal doses. In repeated dose studies the only effects were reduced body weight gain. Effects on survival and weight gain in the F1 and F2 generations in a reproductive toxicity study were observed at doses of 500 mg/kg bw/d and above. Effects in a developmental study were only observed at doses that were maternally toxic.
In addition, mutagenicity studies using both in vitro and in vivo methods demonstrate that the test substance was not mutagenic.
Because of the lack of significant toxicity observed in the suite of toxicity tests, the DNEL derivation was focused on the worst case situations, that is, long-term exposure to workers via both the oral and dermal routes. The NOAEL used to derive the DNELs was the lowest NOAEL from the reproductive toxicity chronic test with rats. The calculated DNELlong-term values for dermal and inhalation exposures were 9.6 mg/kg bw/day and 7.0 mg/m3, respectively. The calculated DNELlong-term values for consumer oral, dermal and inhalation exposures were 0.5 mg/kg bw/day, 4.8 mg/kg bw/day and 1.8 mg/m3, respectively
Benzene, C15 -16 -alkyl derivs. is not classified for any of the human health endpoints, nor is it classified as a PBT or vPvB. Benzene, C15 -16 -alkyl derivs. is classified for aspiration hazard due to its low viscosity and therefore exposure and risk characterizations have been completed.
DNEL long-term, consumers, inhalation
For this DNEL, a similar procedure is applied as for the derivation of the other DNELs. However, since no long-term inhalation toxicity data are available, the oral NOAEL must first be converted to an inhalation value to use as the starting point. Using the formula for the general population in Figure R.8-3 of Chapter R.8 (p.27) and the oral NOAEL of 50 mg/kg, the resulting inhalation NOAEC would be 44 mg/m3. Because this conversion includes interspecies exposure duration differences, no allometric scaling assessment factor is required. The remaining assessment factors are included as shown in the table below. The resulting DNELlong-term, consumers, inhalation is equivalent to 1.8 mg/m3.
DNEL long-term, consumers, dermal
For long-term, consumer, dermal exposures, the DNEL is derived using the oral NOAEL as the starting point. This starting point oral NOAEL value must be corrected for route-to-route extrapolation. In accordance with REACH guidance document R.8, in the absence of data, no default factor (i.e. factor of 1) should be introduced for oral-to-dermal extrapolation, based on the assumption that dermal absorption will in general not be higher than oral absorption. However, for highly lipophilic substances (log Kow > 4), according to Section R.7.12.2.1 of REACH guidance document R7.C, a 10% default dermal absorption value is recommended for the purpose of risk assessment. Therefore a factor of 9.6 (ABSoral/ABSdermal = 96/10) can be used to correct the starting dose for absorption difference between routes. The next steps consist in applying assessment factors for interpecies difference, intraspecies variation, exposure duration, dose-response and quality of the database. The overall AF in this case again corresponds to 100 (see the table below). The resulting DNELlong-term, consumers, dermal is equivalent to 4.8 mg /kg bw/day.
DNEL long-term, consumers, oral
The starting point oral value is taken from the reproductive toxicity study and is based on reduced survival and reductions in body weight in the F1 and F2 generations. No corrections for route-to-route extrapolation are necessary. Next, assessment factors (AF) are applied for interspecies differences, intraspecies variation, exposure duration, dose-response and quality of the database, as described in Section R.8.4.3 of REACH guidance document R.8. For consumers, the general population AF of 10 is used for intraspecies variation. Because of this, the overall AF in this case corresponds to 100 (see the table below). The resulting DNELlong-term, consumers, oral is equivalent to 0.5 mg /kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.